Thursday, October 31, 2019

Know More About Diabetic Ketoacidosis


Diabetic Ketoacidosis Is Preventable With Proper Treatment

Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences



Diabetes is 1 of the top 3 common chronic conditions in the United States that leads to death and disability and is the 7th-leading cause of death.
Cancer, diabetes, and heart disease-account for a large portion of the $3.3 trillion annual US health care expenditures. In fact, 90% of these expenditures are due to chronic conditions. About 23 million people in the United States have diabetes, 7 million have undiagnosed diabetes, and 83 million have prediabetes. Untreated diabetes can become life-threatening, and the disease is the No. 1 cause of adult blindness, kidney failure, and lower-limb amputation. Of these life-threatening complications, diabetic ketoacidosis (DKA) is the leading cause of death in type 1 diabetes (T1D) and is preventable with proper treatment.

DKA is characterized by hyperglycemia (>250 mg/dL), increased ketones, and metabolic acidosis. DKA develops when diabetes, usually T1D is uncontrolled and the body does not have enough insulin to allow glucose into cells and be used for energy. Once this happens, glucose continues to accumulate in the blood and the liver starts to breakdown fat into ketones. In a rare circumstance, it is possible to have DKA with a blood sugar of less than 200 mg/dL. This is called euglycemic DKA, and it is hypothesized that it could be caused by chronic liver disease, decreased caloric intake, glycogen storage disorders, heavy alcohol consumption, pregnancy, recent insulin use, or recent use of sodium-glucose cotransporter 2 inhibitors.

DKA is a rare, life-threatening condition that can occur with T1D and occasionally type 2 diabetes. DKA is often the first presenting symptom of T1D in children and it is also more common in younger people with T1D, especially those younger than 19. It is estimated that DKA at the initial presentation is between 13% and 80%, varying greatly by region. For example, the frequency of DKA at diagnosis is as high as 67% in Romania and 80% in the United Arab Emirates and as low as 13% to 14% in Sweden. Among people who have T1D, the rate of DKA can be as high as 100% in countries such as Algeria, Morocco, and Tunisia. Some research has found that patients who experience DKA at initial presentation may have been experiencing DKA symptoms for more than 2 weeks. The symptoms may go unrecognized not only by caregivers and patients but by clinicians. Greater awareness of this condition is needed to prevent this disease from progressing into a life-threatening state.

Although T1D only represents about 5% of diabetes, it is 1 of the most common chronic pediatric conditions, and the number of hospitalizations in the US from DKA been increasing. Between 2000 and 2009, the number of hospitalizations from DKA decreased, but between 2009 and 2014 the rate of hospitalizations increased by 54.9%, and people younger than 45 were 27 times more likely to be hospitalized than those older than 65. Interestingly, even though the rate of hospitalization has been increasing in the United States, which could be to the result of a multitude of factors, the in-hospital mortality rate in the United States has been decreasing. Those who survive an episode of DKA may suffer from persistent short-term memory loss and even a decrease in their intelligence quotient.

To prevent the potentially devastating consequences of DKA, it is imperative for clinicians to recognize the signs and symptoms of DKA and T1D and educate caregivers and patients.

Risks for DKA at the time of diabetes diagnosis include being younger than 5 years of age, with some research showing that children younger than 2 years have 3 times the risk of presenting with DKA than children older than 2 years; delayed diagnosis or misdiagnosis; lacking private health insurance; lower socioeconomic status; or residing in areas with a low the occurrence of T1D.
Risk factors for DKA in children with established T1D include being younger than 13 years or female; lack of private health insurance, low socioeconomic background; poor family relations; poor glycemic control; psychiatric conditions; and taking higher insulin dosages.

Presentation symptoms include abdominal pain; altered level of consciousness; the breath that smells like fruit, nail polish, or nail polish remover; coma; decreased appetite or reflexes; difficulty breathing; disorientation; hypothermia; ill appearance, as DKA may coincide with another illness, so watch for chills, cough, fever, or malaise; Kussmaul breathing and/or tachypnea; lethargy; nausea; polyuria; rapid weight loss; signs of dehydration, such as decreased skin turgor, dry mucous membranes or skin, hypotension, and tachycardia; vomiting; weakness; and xerostomia.

Prevention of DKA

Diet: Patients should coordinate with all members of their care team regarding their diet and treatment plan. The care team should ideally include a registered dietician (RD) who can help manage this complex chronic condition. An RD can help improve glycemic control and delay the onset of diabetes complications. Dyslipidemia, hypertension, and nephropathy are associated with hyperglycemia and obesity. Uncontrolled diabetes increases the risk of dental, heart, and kidney disease; foot problems; nerve damage; retinopathy; and stroke. Hypoglycemic episodes can lead to convulsions, death, seizures, or unconsciousness.

Early recognition of the signs and symptoms of hyperglycemia before it evolves into DKA.

Exercise:  About 60% of those with T1D are obese or overweight and have dyslipidemia, 40% have hypertension and most are physical underactive. Patients should discuss how to start an exercise routine with their care team to maintain safe blood glucose levels.

Proper insulin use:  Managing T1D is complex and requires careful titration of insulin dosages, which can vary by comorbidities, development, illness, periods of growth, physical activity, and various other factors. Patients should also discuss with their care team how often and when to check blood sugars.


Sufficient dietary fiber intake: Fiber can help patients manage diabetes by delaying or reducing glucose absorption, improving low-density lipoprotein cholesterol and minimizing post-prandial glycemic spikes.


Contact Us: +441234982406 / +441888370010

Thursday, September 26, 2019

Eating fresh fruits and vegetables can benefit an overactive thyroid.

Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences


A person's diet can have an effect on the symptoms of hyperthyroidism. Some foods can improve the condition, while others can make symptoms worse or interfere with medications.

Hyperthyroidism, a type of thyrotoxicosis, is a condition in which the thyroid gland produces too much thyroid hormone. Some people refer to this condition as an overactive thyroid. The most common cause of hyperthyroidism is an autoimmune condition called Graves' disease.
The symptoms of an overactive thyroid include unintentional weight loss, anxiety, sweating, frequent bowel movements, difficulty sleeping, and muscle weakness. Hyperthyroidism is much more common in women than in men.

How does diet affect hyperthyroidism?

Eating certain foods will not cure hyperthyroidism, but some nutrients and minerals play a role in managing the underlying condition. Diet can affect both the production of thyroid hormones and how the thyroid functions.
The following nutrients and chemicals are among those that can affect hyperthyroidism:
Iodine, which the thyroid gland uses to produce thyroid hormone. Too much iodine in the diet can increase the production of thyroid hormone.
Calcium and vitamin D are vital because hyperthyroidism can cause problems with bone mineral density.
Foods and drinks containing caffeine can worsen the symptoms of hyperthyroidism.

Join us on Social Media:

Experimental Diabetes Drug may lower Blood Sugar and reduce Obesity

Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences

An experimental drug for treating type 2 diabetes appears to have many beneficial effects. Experiments in animals found that the drug reduces blood sugar levels and the number of mice eats while maintaining muscle mass and increasing bone density.

Type 2 diabetes develops when the body fails to respond to insulin released to lower blood sugar levels. The resulting high blood sugar levels can seriously damage many parts of the body. It’s estimated that 370 million worldwide have type 2 diabetes, and this number is expected to double by 2030 as obesity levels keep rising.

There are already some drugs for treating type 2 diabetes, but better ones are needed. Metformin is widely prescribed to lower blood sugar, for instance, but it does not usually cause weight loss and some people stop taking it because of side effects such as diarrhea and flatulence.

Mark Febbraio at Monash University in Australia and his colleagues have developed an alternative drug based on signaling proteins. These bind to a receptor called gp13 found on many cells in our body and that are known to have beneficial effects on the metabolism.
To create the drug, the team combined parts of two different human signaling proteins and made variously other tweaks to create a designer signaling protein called IC7Fc. When they injected the protein into obese mice, it had multiple beneficial effects including lowering blood sugar levels.

The animals also ate less, lost weight and had increased bone density. This weight loss was due to fat loss; there was no decline in muscle mass. By contrast, obese mice that were simply fed less without getting IC7Fc lost muscle mass as well as fat. In people, losing weight can be enough to restore normal blood sugar levels.

The drug also prevented the build-up of fat in the liver. Initial experiments in monkeys seem to back up the findings.

No existing drug has as many beneficial effects on health and metabolism, the team says, and if it works in people, it could be especially helpful for the elderly because of its effects on muscle and bone.

Because the drug consists of a protein it has to be injected rather than taken in pill form. But only one injection a week would be needed.

More on these topics: Diabetes, Endocrinology, Cardiology, Obesity, and Hypertension

Email & Contact Us: diabetescardiocare@asiapacificmeets.com  | 441234982406




Saturday, September 21, 2019

Know More About Diabetes & Heart Diseases!!!


Diabetes and heart attack is a particularly risky combination

Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences

Diabetes is a growing public health concern. High blood sugar levels slowly attack the artery walls and facilitate deposits of cholesterol. The ensuing lipid-rich plaques can block arteries in the heart, brain, and legs, raising the risks of heart attack, stroke, and claudication with possible amputation.


In theory, high blood glucose levels may impair the capacity of heart cells to contract and propel blood throughout the body, leading to heart failure. However, whether patients with diabetes are at greater risk of developing heart failure when suffering a heart attack has not been extensively studied.

The study used data from nationwide surveys carried out in France between 2005 and 2015 in 12,660 patients hospitalised for a heart attack. The researchers analysed whether diabetic patients were more likely than non-diabetic patients to develop heart failure during their hospital stay and in the year after. In patients with diabetes, they compared five-year mortality in those readmitted for nonfatal heart failure during the year following their heart attack versus those who did not develop heart failure.

Nearly 25% of patients hospitalised for an acute myocardial infarction during the ten-year period had known diabetes (3,114 of 12,660 patients). “This figure is consistent with what most cardiologists have found among their heart attack patients and illustrates how common diabetes is,” said Prof Danchin.

During hospitalisation for myocardial infarction, 32% of patients with diabetes developed heart failure compared to 17% of patients without diabetes. After adjusting for other factors that could cause heart failure, those with diabetes had a 56% higher risk than those without of developing heart failure.

Likewise, in those who survived the heart attack, 5.1% of diabetic patients were hospitalised for nonfatal heart failure in the following year compared to 1.8% of non-diabetic patients. After adjustment, this equated to a 44% raised risk of heart failure in those with diabetes.

Finally, among patients with diabetes who were alive one year after their heart attack, 56% of patients who had been hospitalised for heart failure during that year died during the subsequent four years compared to 21% of those without heart failure. After adjustment, this amounted to a 73% higher risk of five-year mortality in those with heart failure. The increased risk was particularly marked for diabetic patients requiring insulin.

Prof Danchin said: “Our study shows that diabetes is associated with a considerably increased risk of developing heart failure after a heart attack. Furthermore, diabetic patients who develop heart failure in the year after a heart attack have a much higher risk of dying in the following years.”

He concluded: “More efforts are needed to prevent diabetes. In addition, better management is required for diabetic patients who have a heart attack to avoid heart failure and its detrimental long-term consequences.”



Friday, September 20, 2019

Dapagliflozin : Treat Diabetes and Heart


Diabetes a drug may also treat heart

 failure, study suggests !!!

Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences



Dapagliflozin, which is used to treat diabetes, can also treat heart failure in patients with and without diabetes, according to researchers in Scotland.

They found that dapagliflozin, a drug already used to successfully treat type 2 diabetes and prevent development of heart failure, can also be used to treat pre-existing heart failure.

They said the clinical implications of the findings from the DAPA-HF study were “huge” for heart failure treatment.

Dapagliflozin is one of the relatively new class of diabetes drugs called Sodium-glucose cotransporter 2 (SGLT-2) inhibitors.
Previous studies have shown that SGLT-2 inhibitors not only help control blood glucose levels, but can also improve a number of cardiovascular outcomes, including promoting weight loss, reducing blood pressure and reducing the risk of cardiovascular mortality.

Dapagliflozin has already been proved to reduce the risk of developing heart failure in patients with type 2 diabetes.
In the new study, researchers analyzed whether the drug could also be used to treat type 2 diabetes patients with established heart failure and also heart failure in patients without type 2 diabetes.

The trial enrolled 4,744 patients with heart failure and reduced ejection fraction in 20 countries, of whom 45% had type 2 diabetes, and 55% did not.

Patients were randomly allocated to either dapagliflozin 10mg once daily or matching placebo. The primary endpoint was a combination of a first episode of worsening heart failure or death from cardiovascular causes.

The treatments in the study were given on top of standard care, with 94% receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker or angiotensin receptor-neprilysin inhibitor, 96% a beta-blocker and 71% a mineralocorticoid receptor antagonist.

The researchers found that, over a median follow-up of 18.2 months, the primary outcome occurred in 16.3% in the dapagliflozin group and in 21.2% in the placebo group, translating to a 26% reduced risk in the dapagliflozin. The results were similar in the groups with type 2 diabetes and without the condition.

Components of the primary outcome were also analysed separately, showing a 30% reduced risk of worsening heart failure in the dapagliflozin group and an 18% lower risk of death from cardiovascular causes. All-cause mortality was reduced by 17%.

Meanwhile, 7.5% in the dapagliflozin group had an adverse event-related to volume depletion, compared to 6.8% in the placebo group, with no significant difference between groups.

Adverse events related to kidney dysfunction occurred in 6.5% of patients in the dapagliflozin group versus 7.2% in the placebo group, with no significant difference between groups.

Major hypoglycaemia and lower limb amputation and fracture were infrequent and occurred at similar rates in the two treatment groups.

Lead study author Professor John McMurray, from the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, said: "The most important finding of all is the benefit in patients without diabetes".

“This shows dapagliflozin is truly a treatment for heart failure and not just a drug for diabetes,” he said.

“Adverse events rarely required the discontinuation of treatment,” he said. There was no notable excess of any serious adverse event in the dapagliflozin group.

“The trial shows that dapagliflozin reduces death and hospitalisation, and improves health-related quality of life, in patients with heart failure and reduced ejection fraction, with and without diabetes.

He added: “The clinical implications are potentially huge – few drugs achieve these results in heart failure and dapagliflozin does even when added to excellent standard therapy.”


To expand knowledge about diabetes and heart diseases, visit our website: https://diabetes-heart-disease.healthconferences.org/



Drop Us Email: cardiovasculardiabetology@asia-meetings.com 
Contact : +44-203-7690-972 | +1-650-889-4686 | +441234982406

Wednesday, September 4, 2019

Patients with Diabetes are at greater risk of Heart Failure!!!

Diabetic Complications:

High levels of sugars or glucose in the blood lead to such a chronic condition called diabetes mellitus. High glucose in the blood may cause eye damage, nerve damage, and kidney damage, loss of sensation in sexual organs (sexual dysfunction). Diabetes increases the risk of various cardiovascular diseases such as coronary artery diseaseheart attackheart stroke and narrowing of arteries which reduces the blood flow through the arteries. In addition to this, people with diabetes have more chances to develop infections that may lead to allergies. Diabetes is the main cause of cardiovascular diseases, kidney failure, and blindness. Diabetes can also cause foot ulcers and hearing problems, people with diabetes have hearing impairment commonly.

Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences


Drop us an email atcardiovasculardiabetology@asia-meetings.com



Friday, August 30, 2019

CHOOSE YOUR SESSION!!!

  Diabetes and Heart: A Culture of Caring


Diabetes Conferences, Cardiology Conferences, Endocrinology Conferences, Heart Conferences, Hypertension Conferences, Obesity Conferences, Cardiovascular Diseases Conferences, Diabetes Congress, Cardiology Congress, Heart Congress, Obesity Congress, Endocrinology Congress, Endocrine Conferences

Submit your abstract to any session of your interest!!!



Whatsapp at: +441234982406